GT Biopharma Business Summary

GT Biopharma, Inc. (GTBP) is a clinical-stage biopharmaceutical company that operates a research-and-development-heavy business model focused on the discovery and commercialization of novel immuno-oncology therapeutics. The company generates value through its proprietary Tri-specific Killer Engager (TriKE®) and Tetra-specific Killer Engager platforms, which are designed to harness a patient's natural killer (NK) cells to target and destroy cancer. Its primary business segments are categorized by therapeutic application: hematologic malignancies (led by GTB-3650 for myeloid leukemias), solid tumors (GTB-5550 targeting B7-H3), and autoimmune disorders (GTB-7550 for lupus). GT Biopharma competes directly with other small-cap biotech innovators such as Finch Therapeutics, Apollomics, and Quince Therapeutics. Within this landscape, GTBP positions itself as a specialized platform-play, leveraging unique camelid-based single-chain variable fragment (scFv) technology to provide a cost-effective, off-the-shelf alternative to complex and expensive CAR-T cell therapies. The company was founded by Anthony Cataldo and David Saloff, with current leadership centered around Executive Chairman and CEO Michael Breen, an English-qualified solicitor with a background as a senior partner at Clyde & Co and Managing Director at Bank Insinger de Beaufort (BNP Paribas Group). The scientific foundation is anchored by Consulting Senior Medical Director Dr. Jeffrey S. Miller, a renowned pioneer in NK cell biology from the University of Minnesota and the primary inventor of the TriKE technology. Financial operations are overseen by CFO Alan L. Urban, who brings over 30 years of experience from roles at Research Solutions and ReachLocal. The Board of Directors includes notable industry veterans such as investment strategist Hilary Kramer, healthcare advisor Charles J. Casamento, and David C. Mun-Gavin, formerly of Credit Suisse and Bankers Trust. Institutional interest is maintained by firms like Citadel Advisors and Geode Capital Management, reflecting an investor base focused on the company's 2026 clinical catalysts and FDA-cleared IND applications.